UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): February 28, 2019
BIO-PATH HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-36333 | 87-0652870 |
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
4710 Bellaire Boulevard, Suite 210, Bellaire, Texas | 77401 |
(Address of principal executive offices) | (Zip Code) |
(832) 742-1357
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01 Regulation FD Disclosure.
On February 28, 2019, Bio-Path Holdings, Inc. (the “Company”) issued a press release titled, “Bio-Path Holdings to Present Data at the 2019 AACR Annual Meeting.” A copy of such press release is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit | ||
Number | Description | |
99.1 | Press Release dated February 28, 2019 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIO-PATH HOLDINGS, Inc. | ||
Dated: February 28, 2019 | By: | /s/ Peter H. Nielsen |
Peter H. Nielsen | ||
President and Chief Executive Officer |
EXHIBIT INDEX
Exhibit | ||
Number | Description | |
99.1 | Press Release dated February 28, 2019 |
Exhibit 99.1
Bio-Path Holdings to Present Data at the 2019 AACR Annual Meeting
HOUSTON—February 28, 2019 – Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting, taking place from March 29 – April 3, 2019 in Atlanta, GA.
Details for the poster presentation are as follows:
Date: Wednesday, April 3, 2019
Presentation Time: 8:00 am – 12:00 pm Eastern Time
Location: Georgia World Congress Center, Exhibit Hall B
Session: Gene- and Vector-Based Therapy, Poster Section 12
Abstract: 4786
Title: “BP1003, A Novel Liposome-Incorporated STAT3 Antisense Oligodeoxynucleotide Inhibitor”
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and in preclinical studies for solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, which the company anticipates entering into clinical studies where it will be evaluated in lymphoma and solid tumors.
For more information, please visit the Company's website at http://www.biopathholdings.com.
# # #
Contact Information:
Investors
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
will@sternir.com
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369
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end